Advertisement

Drugs Useful in the Chemotherapy of the Acute Leukemias

  • R. L. Capizzi
  • K. Agrawal
Part of the Handbook of Experimental Pharmacology book series (HEP, volume 101)

Abstract

Traditionally, the only curative measures for neoplastic diseases have been surgery and/or radiation therapy. These modalities cure only localized forms. Since they are disseminated malignancies, the leukemias require systemic therapy. Collaborative research efforts between chnicians and pharmacologists over the past 30 years have enabled the development of regimens that are curative for several subsets of patients with acute leukemia.

Keywords

Acute Leukemia Cytosine Arabinoside Chronic Leukemia Asparagine Synthetase Phosphoramide Mustard 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abuchowski A, Kazo GM, Verhoest CJ Jr et al. (1984) Cancer therapy with chemically modified enzymes: L Antitumor properties of polyethylene glycolasparaginase conjugates. Cancer Biochem Biophys 7:175–186 (Abstract)PubMedGoogle Scholar
  2. Allegra CJ, Chabner BA, Drake JC, Lutz R, Robard D, Jolivet J (1985a) Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. J Biol Chem 260:9720–9726PubMedGoogle Scholar
  3. Allegra CJ, Drake JC, Jolivet J, Chabner BA (1985b) Inhibition of hosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc Natl Acad Sci USA 82:4881–4885PubMedCrossRefGoogle Scholar
  4. Alt FW, Kellems RE, Schimke RT (1976) Synthesis and degradation of folate reductase in sensitive and methotrexate-resistant lines of S180 cells. J Biol Chem 251:3063–3074PubMedGoogle Scholar
  5. Amadori S, Papa G, Avvisati G (1984) Sequential combination of systemic high-dose ara-C and asparaginase for the treatment of central nervous system leukemia and lymphoma. J Chn Oncol 2:98–101Google Scholar
  6. Andruhs IL, Barrett MT (1989) DNA methylation patterns associated with asparagine synthetase expression in asparagine-overproducing and -auxotrophic cells. Mol Cell Biol 9:2922–2927Google Scholar
  7. Bach M (1969) Biochemical and genetic studies of a mutant strain of mouse leukemia L1210 resistant to l-ß-o-arabinofuranosylcytosine (cytarabine) hydrochloride. Cancer Res 29:1036–1044PubMedGoogle Scholar
  8. Bachur NR (1975) Adriamycin (NSC 123127) pharmacology. Cancer Chemother Rep 6:153Google Scholar
  9. Beidler JL, Riehm H (1970) Cellular resistance to actinomycin D in Chinese hamster cells in vitro: cross-resistance, radioautographic, and cytogenetic studies. Cancer Res 30:1174–1184Google Scholar
  10. Bender R, Castle M, Martiletter D, Oliverio V (1977) The pharmacokinetics of H-vincristine in man. Clin Pharmacol Ther 22:430–438Google Scholar
  11. Benjamin RS (1974) Pharmacokinetics of adriamycin in patients with sarcomas. Cancer Chemother Rep 58:271–273PubMedGoogle Scholar
  12. Berns A, Rubenfeld S, Rymzo WT (1972) Hazard of combining allopurinol and thiopurine. N Engl J Med 286:730–731PubMedGoogle Scholar
  13. Bhushan A, Kermode JC, Posada J, Tritton TR (1989) Anthracycline resistance. Kluwer, Boston, pp 55–72Google Scholar
  14. Bokkerink JPM, Bakker MA, Hulscher TW, De Abreu RA, Schretlen DAM (1988) Purine de novo synthesis as the basis of synergism of methotrexate and 6-mercaptopurine in human malignant lymphoblasts of different lineages. Biochem Pharmacol 37:2321–2327PubMedCrossRefGoogle Scholar
  15. Borsa J, Whitmore GF (1969) Studies reladng to the mode of acdon of methotrexate: IL Studies on sites of acdon on L cells in vitro. Mol Pharmacol 5:303–317PubMedGoogle Scholar
  16. Brockman RW (1963) Mechanism of resistance to anticancer agents. Adv Cancer Res 7:129–234PubMedCrossRefGoogle Scholar
  17. Broome JD (1963) Evidence that the-asparaginase of guinea pig serum is responsible for its andlymphoma effects. J Exp Med 118:99–120PubMedCrossRefGoogle Scholar
  18. Broome JD (1968) Studies on the mechanism of tumor inhibidon by-asparaginase. J Exp Med 127:1055–1072PubMedCrossRefGoogle Scholar
  19. Brunchede H, Krooth RS (1973) Studies on the xanthine oxidase activity of mammahan cells. Biochem Genet 8:341–350CrossRefGoogle Scholar
  20. Burner RC, Low PS (1985) Identificadon and pardal characterizadon of xanthine oxidase transidons of the milk fat globule membrane. Arch Biochem Biophys 240:60–69CrossRefGoogle Scholar
  21. Burton NK, Barnett MJ, Aherne G, Evans J, Douglas I, Lister TA (1986) The effect of food on the oral administradon of 6-mercaptopurine. Cancer Chemother Pharmacol 18:90–91PubMedCrossRefGoogle Scholar
  22. Camiener GW (1968) Studies of the enzymatic deaminadon of ara-cytidine-V. Inhibition in vitro and in vivo by tetrahydrouridine and other reduced pyrimidine nucleosides. Biochem Pharmacol 17:1981–1991PubMedCrossRefGoogle Scholar
  23. Campbell HA, Mashburn LT, Boyse EA, Old LJ (1967) Two-asparaginase from E. coli B., their separadon, purification and andtumor activity. Biochem Genet 6:721–730Google Scholar
  24. Capizzi RL, Cheng YC (1981) Therapy of neoplasia with asparaginase. In: Holcenberg JS, Roberts J (eds) Enzymes as drugs. Wiley, New York, pp 1–24Google Scholar
  25. Capizzi RL, Holcenberg JS (1991) Asparaginase. In: Holland JF, Frei E (eds) Cancer medicine. Lea and Febiger, PhiladelphiaGoogle Scholar
  26. Capizzi RL, Powell BL (1987) Sequendal high dose ara-C and asparaginase versus high dose ara-C alone in the treatment of patients with relapsed and refractory acute leukemias. Semin Oncol 14[Suppl l]:40–50PubMedGoogle Scholar
  27. Capizzi RL, Bertino JR, Handschumacher RE (1970) -asparaginase. Ann Rev Med 21:433PubMedCrossRefGoogle Scholar
  28. Capizzi RL, Berdno JR, Skeel RT et al. (1971) -Asparaginase: clinical, biochemical, pharmacological and immunological studies. Ann Intern Med 74:893–901PubMedGoogle Scholar
  29. Capizzi RL, Yang JL, Cheng T et al. (1983) Alteration of the pharmacokinetics of high dose ara C by its metabohte, high araU in padents with acute leukemia. J Clin Oncol 1:763–771Google Scholar
  30. Capizzi RL, Poole M, Cooper MR et al. (1984) Treatment of poor risk acute leukemia with sequential high dose ara-C and asparaginase. Blood 63:694–700PubMedGoogle Scholar
  31. Capizzi RL, Yang JL, Rathmell JP et al. (1985) Dose-related pharmacologic effects of high dose ara-C and its self-potendadon. Semin Oncol 12[Suppl 3]:65–75PubMedGoogle Scholar
  32. Capizzi RL, Davis R, Powell B et al. (1988) Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia — a cancer and leukemia group B study. J Chn Oncol 6:499–508Google Scholar
  33. Carrico CK, Sartorelli AC (1977) Effects of 6-thioguanine on macromolecular events in regeneradng rat hver. Cancer Research 37:1868–1875PubMedGoogle Scholar
  34. Cass CE, Gaudette LA, Paterson ARP (1974) Mediated transport of nucleosides in human erythrocytes. Specific binding of the inhibitor nitrobenzythioinosine to nucleoside transport sites in the erythrocyte membrane. Biochim Biophys Acta 345:1–10PubMedCrossRefGoogle Scholar
  35. Chabner BA, Myers CE (1989) Clinical pharmacology of cancer chemotherapy. Lippincott, Philadelphia, p 377Google Scholar
  36. Chandrasekaran B, Capizzi RL, Kute TE, Morgan T, Dimling J (1989) Modulation of the metabolism and pharmacokinetics of 1-ß-arabinofuranosylcytosine by 1-ß-arabinofuranosyluracil in leukemic mice. Cancer Res 49:3259–3266PubMedGoogle Scholar
  37. Chen CJ, Chin JE, Veda K et al. (1986) Internal duplication and homology to bacterial transport proteins in the mdr (P-glycoprotein) gene from multidrug-resistant human cells. Cell 47:381–389PubMedCrossRefGoogle Scholar
  38. Chu MY, Fischer GA (1965) Comparative studies of leukemic cells sensitive and resistant to cytosine arabinoside. Biochem Pharmacol 14:333–341PubMedCrossRefGoogle Scholar
  39. Chu MY, Fischer GA (1968) The incorporation of3H-cytosine arabinoside and its effects on murine leukemia cells. Biochem Pharmacol 17:753–767PubMedCrossRefGoogle Scholar
  40. Clarkson B, Krakoff I, Burchenal J et al. (1970) Clinical results of treatment with E. coli-asparaginase in adults with leukemia, lymphorma, and sohd tumors. Cancer 25:279PubMedCrossRefGoogle Scholar
  41. Conter V, Beck WT (1984) Acquisition of multiple drug resistance by CCRF-CEM cells selected for different degrees of resistance to vincristine. Cancer Treat Rep 68:831–836PubMedGoogle Scholar
  42. Cooney DA, Handschumacher RE (1970)-Asparaginase and-asparagine metabolism. Ann Rev Pharmacol 10:421–440Google Scholar
  43. Cowan KH, Goldsmith ME, Levine RM et al. (1982) Dihydrofolate reductase gene amplification and possible rearrangement in estrogen responsive methotrexate-resistant human breast cancer cells. J Biol Chem 257:15079–15086PubMedGoogle Scholar
  44. Crane LR, Jackson R, Avramis VI (1989) DNA hypermethylation studies in CEM/O cells after treatment with therapeutic and sub-therapeutic concentrations of cytosine arabinoside (ara-C). Proc Am Assoc Cancer Res 30:496 (abstr)Google Scholar
  45. Creaven PJ, Allen LM (1975) EPEG, a new antineoplastic epipodophyllotoxin. Chn Pharmacol Ther 19:221–226Google Scholar
  46. Crook TR, Souhami RL, McLean AEM (1986) Cytotoxicity, DNA cross-linking and single strand breaks induced by activated cyclophosphamide and acrolein in human leukemic cells. Cancer Res 46:5029–5034PubMedGoogle Scholar
  47. Crowther D (1971)-asparaginase and human malignant disease. Nature 229:168–171PubMedCrossRefGoogle Scholar
  48. Curt GA, Carney DN, Cowan KH et al. (1983) Unstable methotrexate resistance in human small-cell carcinoma associated with double-minute chromosomes. N Engl J Med 308:199–202PubMedCrossRefGoogle Scholar
  49. Danhauser LL, Rustum YM (1980) Effect of thymidine on the toxicity, antitumor activity, and metabolism of 1-ß-arabinofuranosylcytosine in rats bearing a chemically induced colon carcinoma. Cancer Res 40:1274–1280PubMedGoogle Scholar
  50. Davidson JD, Winter TS (1964) Purine nucleotide pyrophosphorylases in 6-mercaptopurine-sensitive and -resistant human leukemias. Cancer Res 24:261–267PubMedGoogle Scholar
  51. Deffie AM, Batra JK, Goldenberg GJ (1989) Direct correlation between DNA topoisomerase II activity and cytotoxicity in Adriamycin-sensititive and -resistant P388 leukemia cell lines. Cancer Res 49:58–62PubMedGoogle Scholar
  52. DeGraeff A, Slebos RJC, Rodenhuis S (1988) Resistance to cisplatin and analogues: mechanisms and potential clinical implications. Cancer Chemother Pharmacol 22:325–332Google Scholar
  53. De Jong A, Zijlstra JG, De Vries EGE, Mulder NH (1990) Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an Adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 50:304–309PubMedGoogle Scholar
  54. Distasio JA, Niederman RA, Kafkewitz D, Goodman D (1976) Purification and characterization of-asparaginase with anti-lymphoma activity from Vibrio succinogenes. J Biol Chem 251:6929–6933PubMedGoogle Scholar
  55. Dolowy WC, Elrod LM, Ammeraal RN, Schrek R (1967) Toxicity of-asparaginase to resistant and susceptible lymphoma cells in vitro. Proc Soc Exp Biol Med 125:598–601PubMedGoogle Scholar
  56. Drewinko B, Ho DHW, Barranco SC (1972) The effects of arabinosylcytosine on cultured human lymphoma cells. Cancer Res 32:2737–2742PubMedGoogle Scholar
  57. Elion GB, Hitchings GH (1955) The synthesis of 6-thioguanine. J Am Chem Soc 77:1676CrossRefGoogle Scholar
  58. Elion GB, Burgi E, Hitchings GH (1952) Studies on condensed pyrimidine systems: IX. The synthesis of some 6-subsdtuted purines. J Am Chem Soc 74:411–418CrossRefGoogle Scholar
  59. Elion GB (1967) Biochemistry and pharmacology of purine analogs. Fed Proc 26:898–904PubMedGoogle Scholar
  60. Elion GB, Callahan S, Nathan H, Bieber S, Rundles RW, Hitchings GH (1963a) Potentiation by inhibition of drug degradadon: 6-substituted thiopurines and xanthine oxidase. Biochem Pharmacol 12:85–93CrossRefGoogle Scholar
  61. Elion GB, Callahan S, Rundles RW, Hitchings GH (1963b) Reladonship between metabohc fates and andcancer activities of thiopurines. Cancer Res 23:1207–1217PubMedGoogle Scholar
  62. Ellison RR (1982) Acute myelocytic leukemia. In: Holland JF, Frei E (eds) Cancer medicine. Lea and Febiger, Philadelphia, pp 1407–1446Google Scholar
  63. Endicott JA, Ling V (1989) The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu Rev Biochem 58:137–172PubMedCrossRefGoogle Scholar
  64. Endressen L, Schjerven L, Rugstad HE (1984) Tumours from a cell strain with a high content of metallothionein show enhanced resistance against cisdichlorodiamminepladnum. Acta Pharmacol Toxicol 55:183–187CrossRefGoogle Scholar
  65. Farber S, Diamond LK, Mercer RD, Sylvester RF Jr, Wolff JA (1948) Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (Aminopterin). N Engl J Med 238:787PubMedCrossRefGoogle Scholar
  66. Flintoff WF, Essani K (1980) Methotrexate-resistant Chinese hamster ovary cells contain a dihydrofolate reductase with an altered affinity for methotrexate. Biochemistry 19:4321–4327PubMedCrossRefGoogle Scholar
  67. Ford JM, Hait WN (1990) Pharmacology of drugs that alter multidrug resistance in cancer. Pharmacol Rev 42:155–199PubMedGoogle Scholar
  68. Fridland A (1974) Effect of methotrexate on deoxynucleodde pools and DNA synthesis in human lymphocyte cells. Cancer Res 34:1883–1888PubMedGoogle Scholar
  69. Fyfe MJ, Goldman ID (1973) Characteristics of the vincrisdne-induced augmentadon of methotrexate uptake in Ehrlich ascites tumor cells. J Biol Chem 248:5067–5073PubMedGoogle Scholar
  70. Gale RP (1979) Advances in the treatment of acute myelogenous leukemia. N Engl J Med 300:1189–1199PubMedCrossRefGoogle Scholar
  71. Galivan J (1980) Evidence for the cytotoxic activity of polyglutamate derivatives of methotrexate. Mol Pharmacol 17:105–110PubMedGoogle Scholar
  72. Ganapathi R, Grabowski D, Ford J, Heiss C, Kerrigan D, Pommier Y (1989) Progressive resistance to doxorubicin in mouse leukemia L1210 cells with multidrug resistance phenotype: reductions in drug-induced topoisomerase II-mediated DNA cleavage. Cancer Commun 1:217–224PubMedGoogle Scholar
  73. Glisson BS, Ross WE (1987) DNA topoisomerase II: a primer on the enzyme and its unique role as a mulddrug target in cancer chemotherapy. Pharmacol Ther 32:89–106PubMedCrossRefGoogle Scholar
  74. Godowski PJ, Picard D, Yamamoto KR (1988) Signal transducdon and transcriptional reguladon by glucocorticoid receptor-Lex A fusion proteins. Science 241:812–816PubMedCrossRefGoogle Scholar
  75. Goldie JH, Krystal G, Hardey D, Andauskas G, Dedhar S (1980) A methotrexate-insensitive variant of folate reductase present in two lines of methotrexate-resistant L5178Y cells. Eur J Cancer 16:1539–1546PubMedCrossRefGoogle Scholar
  76. Goldman ID, Lichtenstein NS, Oliverio VT (1968) Carrier-mediated transport of the folic acid analogue, methotrexate, in the L1210 leukemia cell. J Biol Chem 243:5007–5017PubMedGoogle Scholar
  77. Goldstein LJ, Galski H, Fojo A et al. (1989) Expression of a multidrug resistance gene in human tumors. J Natl Cancer Inst 81:116–124PubMedCrossRefGoogle Scholar
  78. Goulian M, Bleile B, Tseng BY (1980) Methotrexate induced misincorporation of uracil into DNA. Proc Natl Acad Sci USA 77:1956–1960PubMedCrossRefGoogle Scholar
  79. Grafstrom RH, Tseng BY, Goulian M (1978) The incorporation of uracil into animal cell DNA in vitro. Cell 15:131–140PubMedCrossRefGoogle Scholar
  80. Grant DM, Tang BK, Kalow W (1983) Variability in caffeine metabohsm. Clin Pharmacol Therapeut 33:591–602CrossRefGoogle Scholar
  81. Greco A, Gong SS, Ittmann M, Basilico C (1989) Organization and expression of the cell cycle gene, tsll, that encodes asparagine synthetase. Mol Cell Biol 9:2350–2359PubMedGoogle Scholar
  82. Gunz FW, Henderson ES (1983) Leukemia 4th edn. Grune & Stratton, New YorkGoogle Scholar
  83. Gupta RS (1983) Genetic, biochemical, and cross-resistance studies with mutants of Chinese hamster ovary cells resistant to the anticancer drugs VM-26 and VP16-213. Cancer Res 43:1568–1574PubMedGoogle Scholar
  84. Haim N, Roman J, Nemec J (1986) Peroxidative free radical formation and demethylation of etoposide (VP-16) and teniposide (VM-26). Biochem Biophys Res Commun 135:215–220PubMedCrossRefGoogle Scholar
  85. Hall SW, Friedman J, Legha SS, Benjamin RS, Gutterman JU, Loo TL (1983) Human pharmacokinetics of a new acridine derivative, 4’-(9-acridinylamino) methanesulfon-m-anisdide (NSC 249992). Cancer Res 43:3422–3426PubMedGoogle Scholar
  86. Harris AW, Reynolds EC, Finch LR (1979) Effect of thymidine on the sensitivity of cultured mouse tumor cells to 1-ß-arabinofuranosylcytosine. Cancer Res 5:67–82Google Scholar
  87. Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB (1969a) Asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med 2810:1028–1034Google Scholar
  88. Haskell CM, Canellos GP, Leventhal BG, Carbone PP, Block JB (1969b)Asparaginase resistance in human leukemia-asparagine synthetase. Biochem Pharmacol 18:2578–2580PubMedCrossRefGoogle Scholar
  89. Haskell CM, Canellos GP, Cooney DA, Hansen HH (1970) Biochemical and pharmacologic effects of-asparaginase in man. J Lab Clin Med 75:763–770PubMedGoogle Scholar
  90. Haskell CM, Canellos GP, Cooney DA, Hardesty CT (1972) Pharmacologic studies in man with crystallized-asparaginase. Cancer Chemother Rep 56:611–614PubMedGoogle Scholar
  91. Heinle RW, Welch AD (1948) Experiments with pteroylglutamic acid and pteroylglutamic acid deficiency in human leukemia. J Clin Invest 27:539PubMedGoogle Scholar
  92. Herber S, Lennard L, Lilleyman JD, Maddocks JL (1982) 6-Mercaptopurine: apparent lack of relation between prescribed dose and biological effect in children with leukemia. Br J Cancer 46:138–141PubMedCrossRefGoogle Scholar
  93. Hill BT, Bailey BD, White JC, Goldman ID (1979) Characteristics of transport of 4-amino antifolates and folate compounds by two lines of L5178Y lymphoblasts, one with impaired transport of methotrexate. Cancer Res 39:2440–2446PubMedGoogle Scholar
  94. Hill DL, Bennett LL Jr (1969) Purification and properties of 5-phosphoribosyl pyrophosphate amidotransferase from adenocarcinoma 758 cells. Biochemistry 8:122–130PubMedCrossRefGoogle Scholar
  95. Hill JM, Roberts J, Loeb E, Khan A, MacLellan A, Hill RB (1967) -Asparaginase therapy for leukemia. JAMA 202:882–888PubMedCrossRefGoogle Scholar
  96. Hilton J (1984) Role of aldehyde dehydrogenase in cyclophosphamide-resistant L1210 leukemia. Cancer Res 44:5156–5160PubMedGoogle Scholar
  97. Ho DHW, Frei E (1971) Clinical pharmacology of 1-ß-arabinofuranosylcytosine. Clin Pharmacol Ther 12:944–954PubMedGoogle Scholar
  98. Ho DHW, Thetford B, Carter CJK, Frei E III (1970) Chnical pharmacologic studies of-asparaginase. Clin Pharmacol Ther 11:408–417PubMedGoogle Scholar
  99. Ho DHW, Carter CJK, Thetford B, Frei E III (1971) Distribution and mechanism of clearance of-asparaginase (NSC-109229). Cancer Chemother Rep 55:539–545PubMedGoogle Scholar
  100. Ho DH, Brown NS, Yen A et al. (1986) Chnical pharmacology of polyethylene glycol-asparaginase. Drug Metab Disp 14:349–352Google Scholar
  101. Holcenberg JS, Ericsson L, Roberts J (1978) Amino acid sequence of the diazo-oxonorleucine binding site of Acinetobacter andPseudomonas 7-A glutaminaseasparaginase enzymes. Biochemistry 17:411–417PubMedCrossRefGoogle Scholar
  102. Holcenberg JS, Borella LD, Camitta BM, Ring BJ (1979) Human pharmacology and toxicology of succinylatedAcinetobacter glutaminase-asparaginase. Cancer Res 39:3145–3151PubMedGoogle Scholar
  103. Huennekens FM (1963) The role of dihydrofohc reductase in the metabohsm of one-carbon units. Biochemistry 2:151PubMedCrossRefGoogle Scholar
  104. Jackson DV, Castle MC, Bender RA (1978) Bilhary excretion of vincristine. Clin Pharmacol Ther 24:101–107PubMedGoogle Scholar
  105. Jackson RC, Niethamner D (1977) Acquired methotrexate resistance in lymphoblasts resulting from altered kinetic properties of dihydrofolate reductase. Eur J Cancer 13:567–575PubMedCrossRefGoogle Scholar
  106. Jacobs SA, Derr CJ, Johns DG (1977) Accumulation of methotrexate diglutamate in human hver during methotrexate therapy. Biochem Pharmacol 26:2310–2313PubMedCrossRefGoogle Scholar
  107. Juliano RL, Ling V (1976) A surface glycoprotein moduladng drug permeability in Chinese hamster ovary cell mutants. Biochem Biophys Acta 455:152PubMedCrossRefGoogle Scholar
  108. Juranka PF, Zastawny RL, Ling V (1989) P-glycoprotein: multidrug-resistance and a superfamily of membrane-associated transport proteins. FASEB J 3:2583–2592PubMedGoogle Scholar
  109. Jürgens H, Schwamborn D, Korholz D, Wahn V, Gobel U (1988) Klinische Erfahrungen mit polyathylenglykol-gekoppelterE. cöil-L-asparaginase bei Padenten mit ALL-Mehrfachrezidiv. Klin Padiatr 200:184–189PubMedCrossRefGoogle Scholar
  110. Kartner N, Shales M, Riordan JR (1983a) Daunorubicin-resistant Chinese hamster ovary cells expressing multidrug resistance and a cell-surface P-glycoprotein. Cancer Res 43:4413–4419PubMedGoogle Scholar
  111. Kartner N, Riordan JR, Ling V (1983b) Cell surface P-glycoprotein as associated with mulddrug resistance in mammalian cell hnes. Science 221:1285–1288PubMedCrossRefGoogle Scholar
  112. Kaufman RJ, Bertino JR, Schimke RT (1978) Quandtation of dihydrofolate reductase in individual parental and methotrexate-resistant murine cells: use of a fluorescence activated cell sorter. J Biol Chem 253:5852–5860PubMedGoogle Scholar
  113. Kaufman RJ, Brown PC, Schimke RT (1979) Amplified dihydrofolate reductase genes in unsteady methotrexate-resistant cells are associated with double minute chromosomes. Proc Natl Acad Sci USA 76:5669–5673PubMedCrossRefGoogle Scholar
  114. Kessel D, Hall TC, Wodinsky I (1967) Transport and phosphorylation as factors in the andtumor action of cytosine arabinoside. Science 156:1240–1241PubMedCrossRefGoogle Scholar
  115. Kidd JG (1953) Regression of transplanted lymphomas induced in vivo by means of normal guinea pig serum. J Exp Med 98:565–582PubMedCrossRefGoogle Scholar
  116. Knox RJ, Friedlos R, Lydall DA, Roberts JJ (1986) Mechanism of cytotoxicity of andcancer pladnum drugs: evidence that cw-diamminedichloropladnum (II) and cw-diammine (1,1-cyclobutanedicarboxylato) platinum (II) differ only in the kinetics of their interacdon with DNA. Cancer Res 46:1972–1979PubMedGoogle Scholar
  117. Koishi T, Minowada J, Henderson ES, Ohnuma T (1984) Disdnctive sensitivity of some T-leukemia cell lines to L-asparaginase. Gann 75:275–283PubMedGoogle Scholar
  118. Kurtzberg J, Friedman H, Asselin B et al. (1990) The use of polyethylene glycol-conjugated L-asparaginase in pediatric patients with prior hypersensitivity to nadve L-asparaginase. Proc Am Soc Chn Oncol 9:219 (abstr)Google Scholar
  119. Lampkin BC, Nagao T, Mauer AM (1971) Synchronizadon and recruitment in acute leukemia. J Clin Invest 50:2204–2214PubMedCrossRefGoogle Scholar
  120. Lawrence TS, Canman CE, Maybaum J, Davis MA (1989) Dependence of etoposide-induced cytotoxicity and topoisomerase Il-mediated DNA strand breakage on the intracellular ionic environment. Cancer Res 49:4775–4779PubMedGoogle Scholar
  121. Lazarus HM, Herzig RH, Herzig GP, Phillips GL, Roessmann U, Fishman DJ (1981) Central nervous system toxicity of high-dose systemic cytosine arabinoside. Cancer 48:2577–2582PubMedCrossRefGoogle Scholar
  122. Leclerc JM, Cheng YC (1985) Purificadon and characterizadon of a human myeloblast DNA exonuclease activity which could remove 1-ß-D-arabinofuranosylcytosine (ARAC) from DNA with ARAC at 3’terminal. Proc Am Assoc Cancer Res 26:52 (abstr)Google Scholar
  123. Lee MH, Huang YM, Sartorelli AC (1978a) Alkaline phosphatase activides of 6-thiopurine-sensitive and -resistant sublines of sarcoma 180. Cancer Res 38:2413–2418PubMedGoogle Scholar
  124. Lee MH, Huang YM, Sartorelli AC (1978b) Immunological studies on alkahne phosphatases of 6-thiopurine-sensidve and -resistant sublines of sarcoma 180. Cancer Res 38:2419–2423PubMedGoogle Scholar
  125. Lennard L, Lilleyman JS (1987) Are children with lymphoblasdc leukaemia given enough 6-mercaptopurine? Lancet 3:785–787CrossRefGoogle Scholar
  126. Lennard L, Lilleyman JS (1989) Variable mercaptopurine metabolism and treatment outcome in childhood lymphoblastic leukemia. J Clin Oncol 7:1816–1823Google Scholar
  127. Lennard L, Rees CA, Lilleyman S, Maddocks JL (1983) Childhood leukaemia: a relationship between intracellular 6-mercaptopurine metabohtes and neutropenia. Br J Clin Pharmacol 16:359–363PubMedGoogle Scholar
  128. Lennard L, Keen D, Lilleyman JS (1986) Oral 6-mercaptopurine in childhood leukemia: parent drug pharmacokinetics and active metabohte concentradon. Chn Pharmacol Ther 40:287–292CrossRefGoogle Scholar
  129. Lennard L, Van Loon JA, Lilleyman JS, Weinshilboum RM (1987) Thiopurine pharmacogenetics in leukaemia: correlation of erythrocyte thiopurine methyltransferase activity and 6-thioguanine nucleotide concentration. Clin Pharmacol Ther 41:18–25PubMedCrossRefGoogle Scholar
  130. Levitt M, Mosher MB, DeCond RC et al. (1973) Improved therapeutic index of methotrexate with “leucovorin rescue”. Cancer Res 33:1729–1734PubMedGoogle Scholar
  131. Lilleyman JS, Lennard L, Rees CA, Morgan G, Maddocks JL (1984) Childhood lymphoblasdc leukaemia: sex difference in 6-mercaptopurine udlizadon. Br J Cancer 49:703–707PubMedCrossRefGoogle Scholar
  132. Ling V, Thompson CH (1973) Reduced permeability in CHO cells as a mechanism of resistance to colchicine. J Cell Physiol 83:103–116CrossRefGoogle Scholar
  133. Lippman ME, Yarbro GIK, Leventhal BG (1978) Clinical implications of glucocordcoid receptors in human leukemias. Cancer Res 38:4251–4256PubMedGoogle Scholar
  134. Litwack G (1988) The glucocorticoid receptor at the protein level. Cancer Res 48:2636–2640PubMedGoogle Scholar
  135. Ludlum DB (1977) Alkylating agents and the nitrosoureas. In: Becker FF (ed) Cancer: a comprehensive treadse, 5th edn. Plenum, New York, pp 285–307Google Scholar
  136. Markovits J, Pommier Y, Kerrigan D (1987) Topoisomerase Il-mediated DNA breaks and cytotoxicity in relation to cell prohferation and the cell cycle in NIH 3T3 fibroblasts and L1210 leukemia cells. Cancer Res 47:2050–2055PubMedGoogle Scholar
  137. Marmont AM, Damasio EE (1970) Recent results in cancer research. Cancer Res 33:296 (abstr)Google Scholar
  138. Mashburn LT, Wriston JC (1964) Tumor inhibitory effect of L-asparaginase from Escherichia coH. Arch Biochem Biophys 105:451–452CrossRefGoogle Scholar
  139. Mathe G, Amiel JL, Schwarzenberg L et al. (1969) Essai de traitment de la leucemie aiguë lymphoblasdque par la L-asparaginase. La Presse Med 77:461–463 (Abstract)Google Scholar
  140. McGuire JJ, Mini E, Hsieh P, Bertino JR (1985) Role of methotrexate polyglutamates in methotrexate and sequential methotrexate-5-fluorouracilmediated cell kill. Cancer Res 45:6395–6400PubMedGoogle Scholar
  141. Melvin WT, Keir HM (1979) Interacdon of 6-thiopurines and thiol containing RNA with a cellulose mercurial. Analydcal Biochemistry 92:324–330CrossRefGoogle Scholar
  142. Meyers MB, Kreis W (1978) Comparison of enzymadc acdvities of two deoxycyddine kinases purified from cells sensitive (P815) or resistant (P815/ara-C) to 1-ß-D-arabinofuranosylcytosine. Cancer Res 38:1105–1112PubMedGoogle Scholar
  143. Miller HK, Salser JS, Balis ME (1969) Amino acid levels following L-asparaginase amidohydrolase (EC.3.5.1.1) therapy. Cancer Res 29:183–187PubMedGoogle Scholar
  144. Mills-Yamamoto C, Luzon GJ, Paterson ARP (1978) Toxicity of combinations of arabinosylcytosine and 3-deazuridine toward neoplastic cells in culture. Biochem Pharmacol 27:181–186PubMedCrossRefGoogle Scholar
  145. Minton NP, Bullman HMS, Scawen MD, Atkinson T, Gilbert HJ (1986) Nucleotide sequence of the Erwinia chrysanthemi NCPPB 1066 L-asparaginase gene (recombinant DNA; Ml3 phage vector; amino acid sequencing; signal peptide, codon utilization; NIF sequence). Gene 46:25–35PubMedCrossRefGoogle Scholar
  146. Momparler RL, Chu MY, Fischer GA (1968) Studies on a new mechanism of resistance of L5178Y murine leukemia cells to cytosine arabinoside. Biochim Biophys Acta 161:481–493PubMedGoogle Scholar
  147. Moore EC, LePage G (1958) The metabohsm of 6-thioguanine in normal and neoplastic tissues. Cancer Res 18:1075–1083PubMedGoogle Scholar
  148. Muggia FM (1989) Overview of carboplatin: replacing, complementing, and extending the therapeutic horizons of cisplatin. Semin Oncol 16:7–13PubMedGoogle Scholar
  149. Myers CE (1976) Role of iron in anthracychne action. In: Hacker MP, Lazo JS, Tritton TR (eds) Organ-directed toxicities of anticancer drugs. Nijhoff, Boston, pp 17–30Google Scholar
  150. Nelson JA, Carpenter JW, Rose LM et al. (1975) Mechanisms of action of 6-thioguanine, 6-mercaptopurine and 8-azaguanine. Cancer Research 35:872Google Scholar
  151. Nyce J (1989) Drug-induced DNA hypermethylation and drug resistance in human tumors. Cancer Res 49:5829–5836PubMedGoogle Scholar
  152. Oettgen HF, Old LJ, Boyse EA et al. (1967) Inhibition of leukemias in man by L-asparaginase. Cancer Res 27:2619–2631PubMedGoogle Scholar
  153. Ohnuma T, Holland JF, Freeman A, Sinks LF (1970) Biochemical and pharmacological studies with asparaginase in man. Cancer Res 30:2297–2305PubMedGoogle Scholar
  154. Ohnuma T, Arkin H, Takahashi I, Andrejczuk A, Roboz J, Holland JF (1982) Biochemical bases of the differential susceptibility of malignant immune cells to asparaginase and to cytosine arabinoside. In: Arnott MS, van Eys J, Wang YM (eds) Molecular interrelations of nutrition and cancer. Raven, New York, pp 105–121Google Scholar
  155. Owellen RJ, Hartke CA, Dickerson RM (1976) Inhibition of tubuhn-microtubule polymerization by drugs of the vinca alkaloid class. Cancer Res 36:1499–1502PubMedGoogle Scholar
  156. Peterson RG, Richardson FF, Handschumacher RE (1977) Structure of peptide from active site region of Escherichia coli L-asparaginase. J Biol Chem 252:2072–2076PubMedGoogle Scholar
  157. Plagemann PGW, Wohlhueter RM (1984) Inhibition of the transport of adenosine, other nucleosides and hypoxanthine in Novikoff rat hepatoma cells by methylxanthines, papaverine, Ne-cyclohexyladenosine and N-phenyhsopropyladenosine. Biochem Pharmacol 33:1783–1788PubMedCrossRefGoogle Scholar
  158. Plagemann PGW, Marz R, Wohlhueter RM (1978) Transport and metabolism of deoxycytidine and 1-ß-D-arabinofuranosylcytosine into cultured Novikoff rat hepatoma cells, relationship to phosphorylation, and regulation of triphosphate synthesis. Cancer Res 38:978–989PubMedGoogle Scholar
  159. Pommier Y, Minford JK, Schwartz RE (1985) Effects of the DNA intercalators 4’-(9-acridinylamino) methanesulfon-m-anisidide and 2-methyl-9-hydroxyellipticinium on topoisomerase-II-mediated DNA strand cleavage and strand passage. Biochemistry 24:6410–6416PubMedCrossRefGoogle Scholar
  160. Pommier Y, Kerrigan D, Schwartz R, Swack JA, McCurdy A (1986) Altered DNA topoisomerase II activity in Chinese hamster cells resistant to topoisomerase II inhibotors. Cancer Res 46:3075–3081PubMedGoogle Scholar
  161. Poplack DG, Reaman GH (1988) Acute lymphoblastic leukemia in childhood. In: Poplack DG (ed) Pediatric clinic of north america, the Leukemias. WB Saunders, Philadelphia, pp 903–932Google Scholar
  162. Powis G (1983) Metabolism, therapeutic effect, on toxicity of anticancer drugs in man. Drug Metab Rev 14:1145–1163PubMedCrossRefGoogle Scholar
  163. Prager MD, Bachynsky N (1968) Asparagine synthetase in normal and mahgnant tissues; correlation with tumor sensitivity to asparaginase. Arch Biochem Biophys 127:645–654PubMedCrossRefGoogle Scholar
  164. Rama-Reddy GV, Goulian M (1971) Inhibition of E. coli DNA polymerase II by ara-CTP. Nature 234:286–288Google Scholar
  165. Rees CA, Lennard L, Lilleyman JS, Maddocks JL (1984) Disturbance of 6-mercaptopurine metabolism by cotrimoxazole in childhood lymphoblastic leukaemia. Cancer Chemother Pharmacol 12:87–89PubMedCrossRefGoogle Scholar
  166. Roberts J, Prager MD, Bachynsky N (1966) The antitumor activity of Escherichia coli-asparaginase. Cancer Res 26:2213–2217PubMedGoogle Scholar
  167. Rosman M, Wilhams HE (1973) Leukocyte purine phosphoribosyl transferases in human leukemia sensidve and resistant to 6-thiopurines. Cancer Res 33:1202–1209PubMedGoogle Scholar
  168. Rosman M, Lee ML, Creasey WA (1974) Mechanisms of resistance to 6-thiopurines in human leukemia. Cancer Res 34:1952PubMedGoogle Scholar
  169. Ross WE, Sullivan DM, Chow KC (1989) Altered function of DNA topoisomerases as a basis for and-neoplasdc drug action. In: DeVita VT, Hellman S, Rosengerg SA (eds) Important advances in oncology, 5th edn. Lippincott, PhiladelphiaGoogle Scholar
  170. Rowe TC, Chen GL, Hsiang YH (1986) DNA damage by andtumor acridines mediated by mammalian DNA topoisomerase-II. Cancer Res 46:2021–2026PubMedGoogle Scholar
  171. Rustum YM (1978) Metabolism and intracellular retendon of 1-ß-D-rabinofuranosylcytosine as predictors of response of animal tumors. Cancer Res 38:543–549PubMedGoogle Scholar
  172. Rutter DA, Wade HE (1971) The influence of isoelectric point of-asparaginase upon its persistence in the blood. Br J Exp Pathol 52:610–614PubMedGoogle Scholar
  173. Scholar EM, Calabresi P (1979) Increased acdvity of alkaline phosphatases in leukemic cells from patients resistant to thiopurines. Biochem Pharmacol 28:445–446PubMedCrossRefGoogle Scholar
  174. Schwartz MK, Lash ED, Oettgen HF, Tomao FA (1970)-Asparaginase activity in plasma and other biological fluids. Cancer 25:244–252Google Scholar
  175. Schwartz SA, Morgenstern B, Capizzi RL (1982) Schedule-dependent synergy and antagonism between high-dose 1-ß-D-arabinofuranosylcytosine and asparaginase in the L5178Y murine leukemia. Cancer Res 42:2191–2197PubMedGoogle Scholar
  176. Scotto KW, Biedler JL, Mclora PW (1986) Amphficadon and expression of genes associated with multidrug resistance in mammalian cells. Science 232:751–755PubMedCrossRefGoogle Scholar
  177. Seeger DR, Smith JM Jr, Hultquist ME (1947) Antagonist for pteroylglutamic acid. J Am Chem Soc 69:2567PubMedCrossRefGoogle Scholar
  178. Seeger DR, Cosulich DB, Smith JM Jr, Hultquist MD (1949) Analogs of pteroylglutamic acid: III. 4-amino derivatives. J Am Chem Soc 71:753CrossRefGoogle Scholar
  179. Sinha BK, Katki AG, Badst G (1987) Differendal formadon of hydroxyl radicals by adiramycin in sensidve and resistant MCF-7 human breast cells: imphcation for the mechanism of acdon. Biochemistry 26:3776–3781PubMedCrossRefGoogle Scholar
  180. Sinha BK, Mimnaugh EG, Rajagopalan S, Myers CE (1989) Adriamycin activation and oxygen free radical formation in human breast tumor cells: protective role of glutathione peroxidase in adriamycin resistance. Cancer Res 49:3844–3848PubMedGoogle Scholar
  181. Sinkule JA, Stewart CF, Crom WR, Melton ET, Dahl GV, Evans WE (1984) Teniposide (VM-26) disposition in children with leukemia. Cancer Res 44:1235–1237PubMedGoogle Scholar
  182. Sirotnak FM, Donsbach RC (1976) Kinedc correlates of methotrexate transport and therapeutic responsiveness in murine tumors. Cancer Res 36:1151–1158PubMedGoogle Scholar
  183. Sladek NE (1988) Metabohsm of oxazaphosphorines Pharmacol Ther 37:301CrossRefGoogle Scholar
  184. Slevin ML, Piall EM, Aherne GW, Johnston A, Sweatman MC, Lister TA (1981) The pharmacokinetics of subcutaneous cytosine arabinoside in patients with acute myelogenous leukemia. Br J Chn Pharmacol 12:507–510Google Scholar
  185. Speyer JL, Green MD, Ward C (1988) A trial of ICRF-1878 to selectively protect against chronic adriamycin cardiac toxicity: rationale and prehminary result of a clinical trial. In: Hacker MP, Lazo JS, Tritton TR (eds) Organ directed toxicities of anti-cancer drugs. Nijhoff, Amsterdam, pp 64–76CrossRefGoogle Scholar
  186. Spiers ASD, Wade HE (1976) Bacterial glutaminase in treatment of acute leukemia. Br Med J 1:1317–1319PubMedCrossRefGoogle Scholar
  187. Srimatkandada S, Medina WD, Cashmore AR et al. (1983) Amphficadon and organization of dihydrofolate reductase in a human leukemic cell line, K-562, resistant to methotrexate. Biochemistry 22:5774–5781PubMedCrossRefGoogle Scholar
  188. Stewart CD, Burke PJ (1971) Cytidine deaminase and development of resistance to arabinosyl cytosine. Nature 233:109–110CrossRefGoogle Scholar
  189. Sulkes A, Collins JM (1987) Reappraisal of some dosage adjustment guideUnes. Cancer Treat Rep 71:229–233PubMedGoogle Scholar
  190. Tanaka S, Robinson EA, Appella E et al. (1988) Structure of amidohydrolases. Amino acid sequence of a glutaminase-asparaginase from Acinetobacter glutaminasificans and preliminary crystallographic data for an asparaginase from Erwinia chrysantemi. J Biol Chem 263:8583–8591PubMedGoogle Scholar
  191. Tattersall MHN, Ganeshaguru K, Hoffbrand AV (1974) Mechanisms of resistance of human acute leukemia cells to cytosine arabinoside. Br J Haematol 27:39–46PubMedCrossRefGoogle Scholar
  192. Terheggen PMAB, Dijkman R, Begg AC et al. (1988) Monitoring of interaction products of cw-diammine-dichloroplatinum (II) and cw-diammine (1,1-cyclobutamedicarboxylato) platinum II with DNA in cells from platinum-treated cancer patients. Cancer Res 48:5597–5603PubMedGoogle Scholar
  193. Theiss JC, Fischer GA (1976) Inhibition of intracellular pyrimidine ribonucleotide reduction by deoxycytidine, arabinosylcytosine and hydroxyurea. Biochem Pharmacol 25:73–79PubMedCrossRefGoogle Scholar
  194. Tidd DM, Patterson ARP (1974) A biochemical mechanism for the delayed cytotoxic reaction of 6-mercaptopurine. Cancer Res 34:738–7460PubMedGoogle Scholar
  195. Tritton TR, Murphree SA, Sartorelli AC (1978) Adriamycin: a proposal on the specificity of drug action. Biochem Biophys Res Commun 84:802PubMedCrossRefGoogle Scholar
  196. Trowsdale J, Hoch JA, Francke U (1980) A methotrexate-resistant subline of mouse L1210 leukemia cells containing high levels of dihydrofolate reductase and with a homogenously staining region on chromosome 4. Oncodev Biol Med 1:369–374Google Scholar
  197. Tsuno T (1983) Reversal of acquired resistance to vinca alkaloids and anthracychne antibiotics. Cancer Treat Rep 67:889–893Google Scholar
  198. Uren JR, Handschumacher RE (1977) Enzyme therapy. In: Becker FF (ed) Cancer -comprehensive treatise. Plenum, New York, pp 457–487Google Scholar
  199. VanDer Blick AM, Baas F, Ten Houte de Lange T (1987) The human mdr3 gene encodes a novel P-glycoprotein homologue and gives rise to alternatively sphced mRNAs in liver. EMBO J 6:3325–3331Google Scholar
  200. Van Diggelen OP, Donahue TF, Shin SL (1979) Basis for differential cellular sensitivity to 8-azaguanine and 6-thioguanine. J Cell Physiol 98:59–72PubMedCrossRefGoogle Scholar
  201. VanEcho DA, Egorin MJ, Aisner J (1989) The pharmacology of carboplatin. Semin Oncol 16:1–6Google Scholar
  202. Viau AT, Abuchowski A, McCoy JR, Kazo GM, Davis FF (1986) Toxicologic studies of a conjugate of asparaginase and polyethylene glycol in mice, rats, and dogs. Am J Vet Res 47:1398–1401PubMedGoogle Scholar
  203. Wade HE, Elsworth R, Herbert D, Keppie J, Sargeant K (1968) A newasparaginase with antitumor activity. Lancet 2:776–777PubMedCrossRefGoogle Scholar
  204. Walsh CT, Craig RT, Agarwal RP (1980) Increased activation of l-ß-o-arabinofuranosylcytosine by hydroxyurea in L1210 cells. Cancer Res 40:3286–3292PubMedGoogle Scholar
  205. Wan SH, Hoffman DH, Azarnoff DL (1974) Pharmacokinetics of 1-ß-D-arabinofuranosylcytosine in humans. Cancer Res 34:392–397PubMedGoogle Scholar
  206. Waring M (1970) Variation of the supercoils in closed circular DNA by binding of antibiotics and drugs: evidence for molecular models involving intercalation. J Mol Biol 54:247PubMedCrossRefGoogle Scholar
  207. Warnick CT, Paterson ARP (1973) Effect of methylthioinosine on nucleotide concentrations in L5178Y cells. Cancer Res 33:1711–1715PubMedGoogle Scholar
  208. Warrell RP, Chou TC, Gordon C, Tan C, Roberts J (1980) Phase I evaluation of succinylated Aotinobacter glutaminase-asparaginase in adults. Cancer Res 39:3145–3151Google Scholar
  209. Warren RD, Nichols AP, Bender RA (1978) Membrane transport of methotrexate in human lymphoblastoid cells. Cancer Res 38:668–671PubMedGoogle Scholar
  210. Weinshilboum RM, Sladek SL (1980) Mercaptopurine pharmacogenetics: monogenic inheritance of erythrocyte thiopurine methyltransferase activity. Am J Hum Genet 32:651–662PubMedGoogle Scholar
  211. Weinstein HJ, Griffin TW, Feeney J, Cohen HJ, Propper RD, Sallan SE (1982) Pharmacokinetics of condnuous intravenous and subcutaneous infusions of cytosine arabinoside. Blood 59:1351–1353PubMedGoogle Scholar
  212. Whelan HA, Wriston JC Jr (1969) Purification and properdes of asparaginase from Escherichia coli B. Biochemistry 8:2386–2393PubMedCrossRefGoogle Scholar
  213. White JC, Loftfield S, Goldman ID (1975) The mechanism of acdon of methotrexate: III. Requirement of free intracellular methotrexate for maximal suppression of [14C]formate incorporadon into nucleic acids and protein. Mol Pharmacol 11:287–297PubMedGoogle Scholar
  214. White JC, Rathmell JP, Capizzi RL (1987) Membrane transport influences the rate of accumulation of cytosine arabinoside in human leukemia cells. J Chn Invest 79:380–387CrossRefGoogle Scholar
  215. Wiley JS, Jones SP, Sawyer WH, Paterson ARP (1982) Cytosine arabinoside influx and nucleoside transport sites in acute leukemia. J Clin Invest 69:479–489PubMedCrossRefGoogle Scholar
  216. Wiley JS, Jones SP, Sawyer WH (1983) Cytosine arabinoside transport by human leukemia cells. Eur J Cancer Chn Oncol 19:1067–1074CrossRefGoogle Scholar
  217. Wilson L, Bamburg JT, Mizel SB, Grisham LM, Crewell KM (1974) Interacdon of drugs with microtubule proteins. Fed Proc 33:158–166PubMedGoogle Scholar
  218. Wolgemuth DJ, Biedler JL, Melera PW (1980) Repetitive DNA sequences in methotrexate- and methasquin-sensitive and -resistant Chinese hamster cell hnes. Biochem Genet 18:655–667PubMedCrossRefGoogle Scholar
  219. Wolpert MK, Damle SP, Brown JE, Sznycer E, Argrawal KC, Sartorelh AC (1971) The role of phosphohydrolases in the mechanism of resistance to 6-thiopurines. Cancer Res 31:1620–1626PubMedGoogle Scholar
  220. Woods JS, Handschumacher RE (1971) Hepadc homeostasis of plasma-asparagine. Am J Physiol 221:1785–1790PubMedGoogle Scholar
  221. Woods JS, Handschumacher RE (1973) Hepadc reguladon of plasma-asparagine. Am J Physiol 224:740–745PubMedGoogle Scholar
  222. Wriston JC Jr (1985) Asparaginase. Methods Enzymol 113:608–617PubMedCrossRefGoogle Scholar
  223. Wriston JC Jr, Yellin TO (1973)-Asparaginase: a review. Adv Enzymol 39:185–248Google Scholar
  224. Yang JL, Cheng EH, Capizzi RL, Cheng YC, Kute T (1985) Effect of uracil arabinoside on metabolism and cytotoxicity of cytosine arabinoside in L5178Y murine leukemia. J Clin Invest 75:141–146PubMedCrossRefGoogle Scholar
  225. Yurek E, Peru D, Wriston JC Jr (1983) On the distribution of plasmaasparaginase. Experienda 39:383–385CrossRefGoogle Scholar
  226. Zimm S, Collins JM, Riccardi R et al. (1983a) Variable bioavailability of oral 6-mercaptopurine: is maintenance chemotherapy in acute lymphoblastic leukaemia being opdmally delivered? N Engl J Med 308:105–109CrossRefGoogle Scholar
  227. Zimm S, Collins JM, O’Neill D, Chabner BA, Poplack DG (1983b) Inhibition of first-pass metabohsm in cancer chemotherapy: interacdon of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 34:810–817PubMedCrossRefGoogle Scholar
  228. Zimmerman TP, Chu LC, Bugge CJL, Nelson DJ, Lyon GM, Elion GB (1974) Idendfication of 6-methylmercaptopurine ribonucleoside 5’-diphosphate and 5’-triphosphate as metabohtes of 6-mercaptopurine in man. Cancer Res 34:221–224Google Scholar
  229. Zittoun R, Zittoun J, Marquet J, Rustum Y, Creaven P (1985) Modulation of 1-ß-arabinofuranosylcytosine metabohsm by thymidine in human acute leukemia. Cancer Res 45:5186–5192PubMedGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • R. L. Capizzi
  • K. Agrawal

There are no affiliations available

Personalised recommendations